Crystallization of aurora/LPL1P-related kinase
Provided are crystals relating to Aurora/LPL1P-related kinase and its various uses.
1. A composition comprising a protein in crystalline form wherein the protein consists of residues 24-295 of SEQ ID NO: 3, wherein said protein is in complex with a ligand that is bound to the ATP binding site of the protein, and wherein the protein crystal has a crystal lattice in a P6 1 22 space group and unit cell dimensions, +/−2%, of a=80.45 Å, b=80.45 Å and c=172.18 Å.
2. The composition according to claim 1 wherein the protein crystal diffracts X-rays for a determination of structure coordinates to a resolution of a value equal to or less than 3.0 Angstroms.
3. A method for forming a crystal of a protein comprising:
forming a crystallization volume comprising a precipitant solution and a protein that consists of residues 24-295 of SEQ ID NO:3;
storing the crystallization volume under conditions suitable for crystal formation of the protein; and
forming a protein crystal, wherein said protein is in complex with an ATP binding site ligand and wherein the protein crystal has a crystal lattice in a P6 1 22 space group and unit cell dimensions, +/−2%, of a=80.45 Å, b=80.45 Å and c=172.18 Å.
4. The method according to claim 3 wherein the formed protein crystal diffracts X-rays for a determination of structure coordinates to a resolution of a value equal to or less than 3.0 Angstroms.
5. The method according to claim 3 , wherein a protein crystal is formed, the method further comprising diffracting the protein crystal to produce a diffraction pattern and solving the structure of the protein from the diffraction pattern.
6. The method according to claim 5 , the method further comprising:
performing rational drug design using the solved structure; and
identifying an entity that potentially associates with the protein.
7. The method according to claim 6 further comprising selecting one or more entities based on the rational drug design and contacting the selected entities with the protein.
8. The method according to claim 7 further comprising measuring an activity of the protein when contacted with the one or more entities.
9. A noncrystalline protein consisting of SEQ ID NO:3.
10. A non-crystalline protein consisting of residues 24-295 of SEQ ID NO:3.
11. An isolated noncrystalline protein consisting of residues 24-295 of SEQ ID NO:3.
12. An isolated noncrystalline protein consisting of SEQ ID NO:3.